COST-UTILITY ANALYSIS OF DELAYED-RELEASE DIMETHYL FUMERATE FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN PORTUGAL

被引：2
|
作者：
Silva Miguel, L. [1 ]
de Sa, J. [2 ]
Pinheiro, B. [1 ]
Acosta, C. [3 ]
机构：
[1] CISEP Res Ctr Portuguese Econ, Lisbon, Portugal
[2] Ctr Hosp Lisboa, Lisbon, Portugal
[3] Biogen Idec Inc, Lisbon, Portugal
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 07期
关键词：
D O I：
10.1016/j.jval.2015.09.2471
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PND56
引用
收藏
页码：A758 / A758
页数：1
相关论文
共 50 条
  • [41] COST-UTILITY OF DISEASE MODIFYING THERAPIES FOR RELAPSING -REMITTING MULTIPLE SCLEROSIS
    Zimmermann, M.
    Brouwer, E.
    Tice, J. A.
    Seidner, M.
    Loos, A.
    Liu, S.
    Chapman, R. H.
    Kumar, V
    Carlson, J. J.
    VALUE IN HEALTH, 2017, 20 (05) : A193 - A193
  • [42] Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies
    Havrdova, E.
    Giovannoni, G.
    Gold, R.
    Fox, R. J.
    Kappos, L.
    Phillips, J. Theodore
    Okwuokenye, M.
    Marantz, J. L.
    EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 (05) : 726 - 733
  • [43] Cost-utility of interferon β1b in the treatment of patients with active relapsing-remitting or secondary progressive multiple sclerosis
    G. Kobelt
    L. Jönsson
    S. Fredrikson
    The European Journal of Health Economics, 2003, 4 (1) : 50 - 59
  • [44] Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United States
    Mauskopf, Josephine
    Fay, Monica
    Iyer, Ravi
    Sarda, Sujata
    Livingston, Terrie
    JOURNAL OF MEDICAL ECONOMICS, 2016, 19 (04) : 432 - 442
  • [45] Cost-utility and cost-effectiveness analysis of disease-modifying drugs of relapsing-remitting multiple sclerosis: a systematic review
    Gallehzan, Nasrin Abulhasanbeigi
    Khosravi, Majid
    Jamebozorgi, Khosro
    Mir, Nazanin
    Jalilian, Habib
    Soleimanpour, Samira
    Hoseini, Saeed
    Rezapour, Aziz
    Eshraghi, Abbas
    HEALTH ECONOMICS REVIEW, 2024, 14 (01)
  • [46] COST-UTILITY OF CLADRIBINE TABLETS AND DIMETHYL FUMARATE IN THE TREATMENT OF RELAPSING REMITTING MULTIPLE SCLEROSIS FROM THE SOCIETAL PERSPECTIVE IN SPAIN
    Ginestal, R.
    Duran, O.
    Rubio-Terres, C.
    Rubio-Rodriguez, D.
    De Los Santos, H.
    Ordonez, C.
    Sanchez, I
    VALUE IN HEALTH, 2022, 25 (12) : S170 - S171
  • [47] COST-UTILITY ANALYSIS OF TERIFLUNOMIDE IN NAIVE VS. PREVIOUSLY TREATED PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN ITALY
    Lazzaro, C.
    Bergamaschi, R.
    Zaffaroni, M.
    Totaro, R.
    Paolicelli, D.
    VALUE IN HEALTH, 2020, 23 : S631 - S631
  • [48] COST-UTILITY ANALYSIS OF DIMETHYL FUMARATE AS A FIRST SWITCH TREATMENT FOR RELAPSING REMITTING MULTIPLE SCLEROSIS IN THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM
    Fahham, L.
    Murta, L.
    Teich, V
    Machado, M.
    Serafini, P.
    VALUE IN HEALTH, 2016, 19 (03) : A61 - A61
  • [49] PATIENT CHARACTERISTICS AND TREATMENT ADHERENCE AMONG PATIENTS TREATED WITH DELAYED-RELEASE DIMETHYL FUMARATE FOR RELAPSING REMITTING MULTIPLE SCLEROSIS IN ISRAEL
    Desai, U.
    Huang, M.
    Kirson, N. Y.
    King, S.
    Hellstern, M.
    Schonfeld, S.
    Birnbaum, H. G.
    Lee, A.
    VALUE IN HEALTH, 2017, 20 (05) : A195 - A195
  • [50] Cost-utility analysis of teriflunomide in naive vs. previously treated patients with relapsing-remitting multiple sclerosis in Italy
    Lazzaro, Carlo
    Bergamaschi, Roberto
    Zaffaroni, Mauro
    Totaro, Rocco
    Paolicelli, Damiano
    NEUROLOGICAL SCIENCES, 2022, 43 (08) : 4933 - 4944
12345